Gastroenterology & GI Surgery

Welcome to the Mayo Clinic Gastroenterology & GI Surgery Page! With one of the largest group of digestive disease specialists in the world, Mayo Clinic has been recognized as the nation's best Gastroenterology & GI Surgery hospital by U.S. News & World Report.
Follow the page to read shared experiences, learn about clinical trials and up-to-date research, and find resources for all your gastroenterology needs. Our goal is to connect you to others, and become informed decision makers; so post a comment, share your story, own your health.

PUBLIC PAGE
Fri, Jun 30, 2017 11:42pm

FDA Approves Biosimilar to Humira

By Kanaaz Pereira, Connect Moderator, @kanaazpereira

The FDA recently approved a biosimilar (trade name, Amjevita) to Humira (adalimumab). A biosimilar is a biological product that is highly similar to the originator drug, and has no clinical differences in terms of safety and effectiveness. Dr. Edward Loftus , M.D., talks about the potential of this drug to offer patients with chronic inflammatory diseases such as Crohn's and ulcerative colitis an additional treatment option, and explains the issues surrounding it.

For more information about IBD, visit mayoclinic.org/IBD.

Dr. Loftus is a gastroenterologist at Mayo Clinic.

Most of the information in this video is correct; however, the manufacturers of the biosimilar and the original drugs have agreed to hold off on bringing this biosimilar to market for several years. So, although it is technically approved by the FDA, it isn't commercially available at this time. – Ed Loftus, MD July 3, 2018

Please login or register to post a reply.

Invite Others

Send an email to invite people you know to join the Gastroenterology & GI Surgery page.

We'll include this text in the user's invitation.